Other News

Avinger Announces Pantheris SV Limited Launch and Successful Treatment of First Patients in the United States

REDWOOD CITY, Calif., July 29, 2019 (GLOBE NEWSWIRE) — Avinger, Inc. (Nasdaq: AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced that physicians in four U.S. sites have successfully treated several patients with […]

Magenta Medical Closes Funding Round Led by NEA in Its First-Ever Life Sciences Investment in Israel

KADIMA, Israel, July 29, 2019 /PRNewswire/ — Magenta Medical, the developer of heart failure solutions based on proprietary miniaturized blood pump technology, today announced a financing round led by global venture capital firm New Enterprise Associates (NEA), with participation from existing investors, including Pitango Venture Capital, JVC Investment Partners and a group of private […]

Northeast Ohio Man Survives Extreme Cardiac Event, Receives 30+ Defibrillations

News Release Department of Marketing and Communications 11100 Euclid Avenue Cleveland, OH 44106   Northeast Ohio Man Survives Extreme Cardiac Event, Receives 30+ Defibrillations UH Geauga Medical Center team shows perseverance and expertise in incredible effort   A Northeast Ohio man who experienced what likely would have been a deadly […]

Cardiovascular Systems, Inc. Announces Former U.S. Congressman Erik Paulsen Joins Board of Directors

ST. PAUL, Minn.–(BUSINESS WIRE)–Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced the addition of independent board member Erik Paulsen. He replaces director Scott Bartos, who is retiring from the board after […]

Miracor Medical Starts PiCSO-AMI-I Randomized Study in EU

AWANS, Belgium–(BUSINESS WIRE)–Miracor Medical SA (Miracor Medical) today announced the initiation and first patient enrollment in the PICSO-AMI-I study to evaluate the benefits of PiCSO® therapy compared with conventional PCI for the treatment of anterior STEMI patients. The first patient enrolled into this study was treated at Oxford Heart Center, Oxford, […]

BioCardia Signs Exclusive Development Agreement With AstraZeneca

SAN CARLOS, Calif., July 25, 2019 (GLOBE NEWSWIRE) — BioCardia®, Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced it has signed an extension to a 2017 development agreement with AstraZeneca [NYSE:AZN] for BioCardia’s Helix™ biotherapeutic delivery catheter system. Under the terms of the initial pre-clinical […]

Eko Launches ‘Eko Home,’ a Cardiac Remote Monitoring Application Enabling Powerful Drug-Data Combinations to Enhance Clinical Studies and Pharmaceutical Trials

San Francisco, July 25, 2019 (GLOBE NEWSWIRE) — Eko, a Silicon Valley-based digital health company applying machine learning in the fight against heart disease, today announced Eko Home, a first-of-its-kind service that enables precise remote monitoring of cardiac function using ECG and heart sounds. Eko Home can be used to create […]

AliveCor Appoints Priya Abani as Chief Executive Officer; Elevates Vinod Khosla to Chairman of the Board

MOUNTAIN VIEW, Calif., July 24, 2019 /PRNewswire/ — AliveCor, the leader in FDA-cleared consumer electrocardiogram technology, today announced the appointment of Priya Abani as Chief Executive Officer. Abani comes to the company with decades of experience creating scale in digital platform technologies. Most recently, Abani was the General Manager for Devices and Enablement at […]

U.S. FDA Accepts Correvio’s Resubmitted New Drug Application For Brinavess (vernakalant)

VANCOUVER, July 25, 2019 /PRNewswire/ – Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmitted New Drug Application (NDA) for Brinavess™ (vernakalant hydrochloride, IV), an antiarrhythmic drug for the rapid conversion […]